Skip to main content
Publications
Hansford HJ, Cashin AG, Jones MD, Swanson SA, Islam N, Douglas SRG, Rizzo RRN, Devonshire JJ, Williams SA, Dahabreh IJ, Dickerman BA, Egger M, Garcia-Albeniz X , Golub RM, Lodi S, Moreno-Betancur M, Pearson SA, Schneeweiss S, Sterne JAC, Sharp MK, Stuart EA, Hernan MA, Lee H, McAuley JH. Reporting of observational studies explicitly aiming to emulate randomized trials: a systematic review . JAMA Netw Open. 2023 Sep 5;6(9):e2336023. doi: 10.1001/jamanetworkopen.2023.36023
Aparicio J, Virgili Manrique AC, Capdevila J, Munoz Boza F, Galvan P, Richart P, Oliveres H, Paez D, Hernando J, Serrano S, Vera R, Hernandez‑Yague X, Gallego RA, Riesco‑Martinez MC, Garcia de Albeniz Martinez X , Maurel J. Randomized phase II trial of FOLFIRI‑panitumumab compared with FOLFIRI alone in patients with RAS wild‑type circulating tumor DNA metastatic colorectal cancer beyond progression to first‑line FOLFOX‑panitumumab: the BEYOND study (GEMCAD 17‑01) . Clin Trans Oncol. 2022 Nov;24(11):2155-65. doi: 10.1007/s12094-022-02868-x
Armstrong MA, Raine-Bennett T, Reed SD, Gatz J, Getahun D, Schoendorf J, Postlethwaite D, Fassett MJ, Peipert JF, Saltus CW , Merchant M, Alabaster A, Zhou X , Ichikawa L, Shi JM, Chiu VY, Xie F, Hunter S, Wang J , Ritchey ME, Chillemi G, Im TM, Takhar HS, Pisa F, Asiimwe A, Anthony MS . Association of the timing of postpartum intrauterine device insertion and breastfeeding with risks of intrauterine device expulsion . JAMA Netw Open. 2022 Feb 28;5(2):e2148474. doi: 10.1001/jamanetworkopen.2021.48474
Goyal RK , Cuyun Carter G, Nagar SP , Nash Smyth E, Price GL, Parikh RC , Huang YJ, Li L, Davis KL , Kaye JA. Treatment patterns, adverse events, and direct and indirect economic burden in a privately insured population of patients with HR+/HER2- metastatic breast cancer in the United States . Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):699-710. doi: 10.1080/14737167.2020.1804871